What is Truvian Sciences?
Founded in 2015, Truvian Sciences is positioned at the intersection of medical diagnostics and digital health. The company is developing an FDA-cleared, automated benchtop system that streamlines the diagnostic process, effectively decentralizing laboratory testing. By enabling practitioners to deliver comprehensive health data to patients in real-time, Truvian is addressing critical inefficiencies in the current healthcare delivery model. Its technology is engineered to provide a seamless, user-friendly experience, bridging the gap between complex clinical diagnostics and accessible, patient-centric care. As the firm scales, its focus remains on enhancing diagnostic accuracy while reducing the time and cost associated with traditional laboratory workflows.
How much funding has Truvian Sciences raised?
Truvian Sciences has raised a total of $207.1M across 4 funding rounds:
Series B
$27.1M
Debt
$1M
Series C
$105M
Other Financing Round
$74M
Series B (2019): $27.1M with participation from Tao Capital Management, GreatPoint Energy, DNS Capital, and Domain Associates
Debt (2020): $1M led by PPP
Series C (2021): $105M supported by TYH Ventures, Glen Tullman, and Wittington Ventures
Other Financing Round (2024): $74M featuring Wittington Ventures, GreatPoint Ventures, Medical Excellence Capital, and DNS Capital
Key Investors in Truvian Sciences
Domain Associates
An investment advisory firm established in 1985, specializing in biotech investments and managing multiple venture capital funds focused on biopharmaceutical and diagnostic companies.
DNS Capital
A Chicago-based investment office serving the Pritzker family, focusing on long-term partnerships with entrepreneurs to create lasting value across various business sectors.
Medical Excellence Capital
An early-stage life sciences venture fund that advances precision health innovations by combining experienced investment professionals with a proprietary national medical network.
What's next for Truvian Sciences?
The recent strategic financing round provides Truvian Sciences with the necessary runway to accelerate its regulatory milestones and commercialization efforts. By leveraging this capital, the company is expected to refine its automated platform and expand its footprint within the clinical diagnostics market. Future growth will likely center on scaling manufacturing capabilities and deepening its integration with existing healthcare provider networks. As the firm moves toward broader market adoption, the focus will shift from development to operational excellence, ensuring that its diagnostic solutions meet the rigorous demands of modern clinical environments while maintaining the high standards required for FDA clearance and widespread medical utility.
See full Truvian Sciences company page
